Table 3 CTC karyotyping and chemotherapeutic efficacy of 58 esophageal cancer patients after second 2-cycles chemotherapy
Sample ID | CTC karyotyping post-chemotherapy | CTC number post-chemotherapy | Non-triploid proportion | chemotherapeutic effect | |
|---|---|---|---|---|---|
Triploid | No-triploid | ||||
2 | > 4 | 0 | 3 | 1 | SD |
3 | 3 | 3 | 0 | 0 | SD |
5 | 3 | 3 | 0 | 0 | PR |
8 | > 4 | 0 | 4 | 1 | PD |
9 | 3 | 2 | 0 | 0 | PR |
11 | 3,  > 4 | 1 | 2 | 0.667 | SD |
12 | 3 | 2 | 0 | 0 | PR |
13 | 3 | 2 | 0 | 1 | SD |
14 | 3,  > 4 | 2 | 2 | 0.5 | SD |
15 | 3,4 | 2 | 3 | 0.6 | SD |
16 | 3 | 3 | 0 | 0 | PR |
17 | 3 | 2 | 0 | 0 | PR |
18 | 3, 4 | 5 | 4 | 0.444 | SD |
19 | 3,  > 4 | 2 | 1 | 0.333 | PD |
20 | 3 | 1 | 0 | 0 | PR |
22 | 3 | 2 | 0 | 0 | PR |
23 | 3 | 3 | 0 | 0 | PR |
26 | 3,4 | 2 | 2 | 0.5 | SD |
28 | 3, 4 | 1 | 2 | 0.667 | SD |
29 | 3,  > 4 | 1 | 2 | 0.667 | PD |
30 | 3 | 3 | 0 | 0 | SD |
31 | 4 | 0 | 2 | 1 | PD |
32 | 3 | 1 | 0 | 0 | PR |
34 | 3 | 2 | 0 | 0 | PD |
35 | 4 | 0 | 2 | 1 | SD |
36 | 3 | 1 | 0 | 0 | PR |
38 | > 4 | 0 | 1 | 1 | SD |
39 | 4 | 0 | 1 | 1 | PD |
41 | 3 | 2 | 0 | 0 | SD |
42 | 3 | 1 | 0 | 0 | PR |
44 | > 4 | 0 | 2 | 1 | SD |
45 | 4 | 0 | 2 | 1 | PD |
46 | 3,  > 4 | 1 | 1 | 0.5 | SD |
47 | 4,  > 4 | 0 | 10 | 1 | PD |
48 | 3, > 4 | 1 | 1 | 0.5 | PR |
49 | 3 | 2 | 0 | 0 | PR |
51 | 3, 4 | 1 | 3 | 0.75 | PD |
52 | 3 | 1 | 0 | 0 | PR |
53 | > 4 | 0 | 1 | 1 | PD |
54 | 3 | 2 | 0 | 0 | PR |
56 | > 4 | 0 | 1 | 1 | PD |
58 | 3 | 1 | 0 | 0 | PR |
59 | 3, | 2 | 0 | 0 | PR |
60 | > 4 | 0 | 1 | 1 | PD |
61 | 3, 4 | 2 | 1 | 0.333 | PR |
62 | 3,4,  > 4 | 2 | 2 | 0.5 | SD |
63 | 3,  > 4 | 1 | 1 | 0.5 | SD |
65 | 3,  > 4 | 1 | 3 | 0.75 | PD |
66 | 3 | 3 | 0 | 0 | PD |
69 | 3, 4, > 4 | 2 | 4 | 0.667 | SD |
70 | 3, 4,  > 4 | 15 | 9 | 0.375 | PD |
71 | 3, 4 | 1 | 2 | 0.667 | PD |
73 | 3,4,  > 4 | 6 | 9 | 0.6 | PD |
74 | Â | 0 | 0 | 0 | PR |
75 | 3 | 3 | 0 | 0 | SD |
76 | 3, 4 | 1 | 1 | 0.5 | PD |
77 | 3 | 1 | 0 | 0 | PR |
78 | > 4 | 0 | 1 | 1 | PD |